Parkman Healthcare Partners’s Bright Minds Biosciences DRUG Stock Holding History

Parkman Healthcare Partners’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.93M	Buy	+40,098	New	+$3.23M	0.3%	77

Other funds holding DRUG

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Parkman Healthcare Partners's DRUG Position: Q1 2026 in Review

Parkman Healthcare Partners opened a new position in Bright Minds Biosciences (DRUG) in Q1 2026: 40,098 shares worth $2.93M. The stake represents 0.3% of the portfolio and ranks #77 among its holdings.

94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

Parkman Healthcare Partners held 40,098 shares of Bright Minds Biosciences worth $2.93M as of Q1 2026.
Bright Minds Biosciences was a new Parkman Healthcare Partners position in Q1 2026.
Bright Minds Biosciences made up 0.3% of Parkman Healthcare Partners's portfolio in Q1 2026, its #77 holding.
94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.